{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T06:21:28Z","timestamp":1791699688558,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1136\/ard.2005.035279","type":"journal-article","created":{"date-parts":[[2005,4,21]],"date-time":"2005-04-21T00:24:31Z","timestamp":1114043071000},"page":"1773-1779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?"],"prefix":"10.1016","volume":"64","author":[{"given":"J U","family":"Holle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W L","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Csernok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.035279_bib1","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","article-title":"Prediction of relapses in Wegener\u2019s granulomatosis by measurement of antineutrophil cytoplasmatic antibody levels","volume":"43","author":"Boomsma","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.035279_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ajcp\/111.4.507","article-title":"International consensus statement on testing and reporting of antineutrophil cytoplasmatic antibodies (ANCA)","volume":"111","author":"Savige","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1136\/ard.2005.035279_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ajcp\/111.3.363","article-title":"Diagnostic usefulness of antineutrophil cytoplasmatic antibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits","volume":"111","author":"Lim","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1136\/ard.2005.035279_bib4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/41.11.1313","article-title":"A critical evaluation of commercial immunoassays for antineutrophil cytoplasmatic antibodies directed against proteinase 3 and myeloperoxidase in Wegener\u2019s granulomatosis and microscopic polyangiitis","volume":"41","author":"Csernok","year":"2002","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2005.035279_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0022-1759(97)00154-3","article-title":"Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmatic antibodies (ANCA)","volume":"208","author":"Wang","year":"1997","journal-title":"J Immunol Methods"},{"key":"10.1136\/ard.2005.035279_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/rheumatology\/keh028","article-title":"Evaluation of Capture ELISA for the detection of antineutrophil cytoplasmatic antibodies directed against proteinase 3 in Wegener\u2019s granulomatosis: first results from a multicenter study","volume":"43","author":"Csernok","year":"2004","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2005.035279_bib7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.035279_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides: The proposal of an International Consensus Conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.035279_bib9","first-page":"671","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"Q J Med"},{"key":"10.1136\/ard.2005.035279_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/40.2.178","article-title":"Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA","volume":"40","author":"Schonermarck","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2005.035279_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"10.1136\/ard.2005.035279_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1523-1755.1998.00807.x","article-title":"Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC\/BCR Project for ANCA Assay Standardization","volume":"53","author":"Hagen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1136\/ard.2005.035279_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/0003-4819-126-11-199706010-00003","article-title":"Prevalence of antineutrophil cytoplasmatic antibodies in a large inception cohort of patients with connective tissue disease","volume":"126","author":"Merkel","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2005.035279_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1046\/j.1365-2249.1997.4561353.x","article-title":"Human mast cells expressing recombinant proteinase 3 (PR3) as substrate testing for anti-neutrophil cytoplasmatic antibodies (ANCA)","volume":"109","author":"Specks","year":"1997","journal-title":"Clin Exp Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724203721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724203721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.035279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:22:12Z","timestamp":1737249732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724203721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S0003496724203721"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.035279","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.035279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}